Genentech’s PFS Data May Help Inavolisib Compete In PI3KCA-Mutated Breast Cancer
Inavolisib meets statistical significance for progression-free survival in HR+/HER2- advanced breast cancer with a PI3KCα mutation, which could set up competition with Piqray, Ibrance and Kisqali.
You may also be interested in...
The UK big pharma gets a first-in-class approval in breast cancer, but a challenger is emerging.
Keeping Track: Novartis Scores Big Ahead Of US Memorial Day With Approvals For Gene Therapy Zolgensma, Oncologic Piqray
The latest drug development news and highlights from our US FDA Performance Tracker.
CDK4/6 inhibitors offer impressive progression-free survival data in breast cancer, but lack of overall survival data may mean the class will be relegated to the second-line setting.